Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $150.5M as of March 31 to fund its operations into early 2027. This cash runway guidance is based on the company’s current operational plans and excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes any additional potential dilutive or non-dilutive funding opportunities.
Leave a comment